FDA
-
-
-
-
-
-
-
Moderna (MRNA) PT Raised to $38 at RBC Capital
-
-
-
-
-
-
-
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
-
-
-
-
-
-
-
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
-
-
-
-
-
-
-
EMA panel recommends approval of Moderna's new COVID vaccine mNEXSPIKE
-
-
-
-
-
-
-
FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
-
-
-
-
-
-
-
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
322,088 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

